Table 3. Predictors of time to major liver events or liver-related death (n = 41): univariable and multivariable Cox regression analysis.
| Univariable analysis | Multivariable analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |||
| Male gender vs female | 1.25 | 0.61 | 2.55 | 0.542 | nt | |||
| Transmission mode | ||||||||
| Heterosexual contacts | 1.00 | ne | ||||||
| MSM | 0.34 | 0.04 | 2.92 | 0.326 | ||||
| IVDU | 10.95 | 4.28 | 28.03 | <0.001 | ||||
| Other/unknown | 1.44 | 0.17 | 12.34 | 0.739 | ||||
| Time from HIV diagnosis (+1 yr more) | 1.13 | 1.08 | 1.18 | <0.001 | Ne | |||
| CD4 per cART (cells/μL) | Nt | |||||||
| 0–199 | 1.00 | |||||||
| 200–349 | 1.44 | 0.67 | 3.12 | 0.350 | ||||
| >350 | 1.40 | 0.65 | 3.03 | 0.390 | ||||
| HIV RNA pre ART (log10 copies/mL) | Nt | |||||||
| <4 | 1.00 | |||||||
| 4–4.99 | 1.60 | 0.61 | 4.23 | 0.342 | ||||
| > = 5 | 0.80 | 0.28 | 2.28 | 0.678 | ||||
| CDC stage C vs A/B | 0.66 | 0.26 | 1.68 | 0.381 | Nt | |||
| HCV Ab and HCVRNA | ||||||||
| HCVAb- | 1.00 | 1.00 | ||||||
| HCVAb+ HCVRNA- | - | - | ||||||
| HCVAb+ HCVRNA+ | 10.71 | 4.23 | 27.08 | <0.001 | 2.79 | 0.84 | 9.24 | 0.093 |
| HCVAb+ HCVRNA na | 17.12 | 6.75 | 43.43 | <0.001 | 4.43 | 1.32 | 14.85 | 0.016 |
| FIB-4 at baseline | ||||||||
| <1.45 | 1.00 | 1.00 | ||||||
| 1.45–3.25 | 6.39 | 2.48 | 16.48 | <0.001 | 3.55 | 1.09 | 11.58 | 0.035 |
| >3.25 | 30.62 | 12.29 | 76.28 | <0.001 | 4.25 | 1.21 | 14.92 | 0.024 |
| Score difference between current fib4 and baseline fib4 (+1 point higher) | 1.02 | 1.00 | 1.08 | 0.013 | Nt | |||
| Current FIB-4 | ||||||||
| <1.45 | 1.00 | 1.00 | ||||||
| 1.45–3.25 | 7.02 | 2.36 | 20.90 | <0.001 | 3.40 | 1.02 | 11.40 | 0.047 |
| >3.25 | 95.23 | 39.15 | 231.65 | <0.001 | 21.24 | 6.75 | 66.84 | <0.001 |
| Alcohol consumption | ||||||||
| No intake | 1.00 | 1.00 | ||||||
| Daily intake | 3.81 | 1.56 | 9.27 | 0.003 | 1.69 | 0.62 | 4.57 | 0.302 |
| Occasional intake | 0.91 | 0.36 | 2.33 | 0.845 | 0.91 | 0.33 | 2.48 | 0.857 |
| Intake without specification | 10.94 | 4.67 | 25.62 | <0.001 | 6.36 | 2.13 | 18.97 | 0.001 |
| Not recorded | 1.63 | 0.54 | 4.94 | 0.383 | 0.60 | 0.12 | 2.93 | 0.531 |
| Blood glucose at baseline | ||||||||
| <126 mg/dL | 1.00 | 1.00 | ||||||
| > = 126 mg/dL | 4.20 | 0.97 | 18.20 | 0.055 | 1.82 | 0.35 | 9.39 | 0.476 |
| Not measured | 1.65 | 0.86 | 3.13 | 0.129 | 2.42 | 0.93 | 6.31 | 0.070 |
| ART type NRTI | ||||||||
| TDF+FTC | 1.00 | 1.00 | ||||||
| ZDV+3TC | 2.06 | 0.58 | 7.30 | 0.260 | 1.92 | 0.40 | 9.15 | 0.413 |
| d4T+3TC | 3.53 | 0.85 | 14.62 | 0.082 | 1.94 | 0.34 | 11.23 | 0.457 |
| d4T+ddI | 5.07 | 1.29 | 19.94 | 0.020 | 2.71 | 0.49 | 15.02 | 0.255 |
| other | 1.37 | 0.33 | 5.64 | 0.664 | 0.41 | 0.06 | 2.81 | 0.361 |
| ART type 3rd drug | ||||||||
| NNRTI | 1.00 | 1.00 | ||||||
| bPI | 0.46 | 0.15 | 1.41 | 0.174 | 0.56 | 0.14 | 2.14 | 0.393 |
| uPI | 0.89 | 0.44 | 1.81 | 0.746 | 0.35 | 0.14 | 0.90 | 0.029 |
| NRTI | 1.37 | 0.31 | 6.08 | 0.678 | 5.35 | 0.73 | 39.45 | 0.100 |
| other | 3.28 | 0.74 | 14.59 | 0.119 | 5.13 | 0.87 | 30.21 | 0.071 |
| Current CD4 (+100 cells/μL higher) | 0.69 | 0.59 | 0.80 | <0.001 | 0.84 | 0.71 | 1.00 | 0.058 |
| Current HIV-RNA (+1 log10 cp/mL higher) | 1.56 | 1.24 | 1.96 | <0.001 | Ne | |||
MSM, men having sex with men; IVDU intravenous drug users; Na, not available; NRTI, nucleos(t)ide reverse transcriptase inhibitors; NNRTI non-nucleoside reverse transcriptase inhibitors; uPI, unboosted protease inhibitors; bPI, boosted protease inhibitors; Ne not entered, rejected by the forward conditional procedure; nt, not tested.